Showing results (241-250 of 300) with videos related to
Sort By:
Pageof 30
The Journal of Pediatrics|March 20, 1998
The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young womenA B Moscicki, S Shiboski, J Broering, et al.Genome Medicine|November 5, 2021
The vaginal microbiota and innate immunity after local excisional treatment for cervical intraepithelial neoplasiaAnita Mitra, David A MacIntyre, Maria Paraskevaidi, et al.Journal of Clinical Epidemiology|January 9, 2022
A case study and proposal for publishing directed acyclic graphs: The effectiveness of the quadrivalent human papillomavirus vaccine in perinatally HIV Infected girlsRuby Barnard-Mayers, Hiba Kouser, Jamie A Cohen, et al.Pediatrics|June 15, 2023
HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV VaccineYi Zeng, Anna-Barbara Moscicki, Heide Woo, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 10, 2012
Sexual risk behavior among youth with perinatal HIV infection in the United States: predictors and implications for intervention developmentKatherine Tassiopoulos, Anna-Barbara Moscicki, Claude Mellins, et al.ISRN Obstetrics and Gynecology|December 23, 2011
Investigating Potential Associations between Cervical Procedures and HIV AcquisitionKhady Diouf, George F Sawaya, Stephen Shiboski, et al.Lancet (London, England)|November 9, 2004
Regression of low-grade squamous intra-epithelial lesions in young womenAnna-Barbara Moscicki, Stephen Shiboski, Nancy K Hills, et al.The International Journal of Eating Disorders|January 5, 2024
Short-term outcomes of the study of refeeding to optimize inpatient gains for patients with atypical anorexia nervosaAndrea K Garber, Jing Cheng, Erin C Accurso, et al.American Journal of Preventive Medicine|February 26, 2021
Effect of 2 Interventions on Cervical Cancer Screening Guideline AdherenceAnna-Barbara Moscicki, Charlene Chang, Sitaram Vangala, et al.BMC Cancer|April 3, 2019
A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocolYi Zeng, Anna-Barbara Moscicki, Vikrant V Sahasrabuddhe, et al.Pageof 30